spacer
home > ebr > summer 2003 > smi conference london march 2003, biologics: overcoming the challenges of development and manufacture
PUBLICATIONS
European Biopharmaceutical Review

SMi Conference London March 2003, Biologics: Overcoming the Challenges of Development and Manufacture

The SMi conference was opened by Dr David Glover, Chief Medical Officer at Cambridge Antibody Technology, who outlined the key challenges for biologics manufacture today: the predicted shortage of manufacturing capacity, the decision to outsource or make in-house, and technical and regulatory challenges.

It is predicted that just 10 monoclonal antibody (mabs) products would consume 75 per cent of the worlds' biologic manufacturing capacity and yet there are 60 mabs likely to emerge onto the market in the next one to seven years. However, the estimate of 400 mabs in clinical trial, which is often quoted, is probably an overestimate, as a single mab can be in clinical trial for a number of different clinical indications. This reduces the current estimate from 400 to around 100. Whilst currently, 30 per cent of FDA drug applications are for biotech drugs, a curious statistic is that biologics produced by pharma/biotech alliances have a 70 per cent greater chance of receiving FDA approval. It is not known whether this is a synergistic effort of the companies working together or if biologic drugs are more likely to get FDA approval than chemical entity-based drugs.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Keith Chidwick, Consultant at Technomark Consulting Services Ltd
spacer
Keith Chidwick
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK

• New offices at leading science hub support the Company’s rapid growth following recent investment • New facility is in addition to headquarters at Babraham Research Campus, Cambridgeshire, UK and offices in Monmouth Junction, New Jersey, USA
More info >>

White Papers

Recommendations Sourcing Human Biospecimens

BioIVT

The foundations for protecting human research subjects come from the ethical principles surrounding the Belmont report : Respect for persons, beneficence, and justice. The use of human biospecimens in research supports these principles with legal and ethical regulations - the most important of which is permission.(1) This permission may come directly from the donor or granted by others with authorization to protect the interests of biospecimen donors.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement